Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET

Company Participants

Karen Hunady - Director, Investor Relations and Corporate Communications

Nancy Simonian - President, CEO & Director

David Roth - Chief Medical Officer

Jason Haas - CFO

Conference Call Participants

Philip Nadeau - TD Cowen

Edward Tenthoff - Piper Sandler & Co.

Jason Butler - JMP Securities

Mark Breidenbach - Oppenheimer

Operator

Good morning, and welcome to Syros Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros.

Karen Hunady

Thank you. This morning, we issued a press release announcing our first quarter 2023 financial results and business update. The full release is available on the Investor and Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Christian Stevens, our Chief Development Officer; Dr. Eric Olson, our Chief Scientific Officer; and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual report on Form 10-K and our quarterly report on Form 10-Q that we filed this morning and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

I would now like to turn the call over to Nancy.

Nancy Simonian

Thank you, Karen. Good morning, everyone, and thank you for joining us today. 2023 is off to a strong start as we focus on clinical execution and move closer to our goal of delivering new standards of care for the frontline treatment of hematologic malignancies. Today, we will be sharing progress with you across our programs in MDS, AML and APL.